RLMD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 13.50%

Insider Buying (Last 12 Months): $382,104.61

Insider Selling (Last 12 Months): $0.00

Relmada Therapeutics Insider Trading History Chart

Relmada Therapeutics Share Price & Price History

^$4.68

▲ +0.12 (2.63%)

As of 04/17/2024 01:00 AM ET

Days: 30 | 90 | 365

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

Relmada Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2024	Maged Shenouda	CFO	Buy	6,875	$4.06	$27,912.50	34,903
1/31/2024	Sergio Traversa	CEO	Buy	27,460	$4.00	$109,840.00	244,024
1/30/2024	Chuck Ence	Insider	Buy	14,500	$3.87	$56,115.00	25,300
1/29/2024	Maged Shenouda	CFO	Buy	10,800	$3.65	$39,420.00	13,028
1/29/2024	Sergio Traversa	CEO	Buy	31,541	$3.71	$117,017.11	175,565
5/23/2023	Cedric O'gorman	Insider	Buy	10,000	$3.18	$31,800.00	10,121
12/8/2022	Sergio Traversa	CEO	Buy	55,250	$2.10	$116,025.00	144,024
6/30/2022	Sergio Traversa	CEO	Sell	16,012	$19.13	$306,309.56	88,774
4/4/2022	Paul Edward Kelly	Director	Sell	10,000	$30.04	$300,400.00	187,295
9/22/2021	Charles J. Casamento	Director	Sell	6,600	$29.00	$191,400.00
7/15/2021	Charles J. Casamento	Director	Sell	3,300	$31.54	$104,082.00	5,854
6/1/2021	Charles J. Casamento	Director	Sell	3,000	$33.34	$100,020.00	9,430

Your Money is Not Safe

From American Alternative | Ad

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

SEC Filings (Institutional Ownership Changes) for Relmada Therapeutics (NASDAQ:RLMD)

45.24% of Relmada Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Relmada Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/16/2024	GSA Capital Partners LLP	184,573	$0.76M	0.1%	-5.5%	0.613%
2/15/2024	Horizon Kinetics Asset Management LLC	30,000	$0.12M	0.0%	N/A	0.100%
2/15/2024	Opaleye Management Inc.	877,000	$3.63M	1.0%	+2,823.3%	2.914%
2/15/2024	Bridgeway Capital Management LLC	170,077	$0.70M	0.0%	+66.7%	0.565%
2/14/2024	ADAR1 Capital Management LLC	58,601	$0.24M	0.1%	N/A	0.195%
2/14/2024	Point72 Asset Management L.P.	250,000	$1.04M	0.0%	N/A	0.831%
2/14/2024	Vestal Point Capital LP	115,000	$0.48M	0.1%	N/A	0.382%
2/14/2024	Schroder Investment Management Group	10,000	$41K	0.0%	N/A	0.033%
2/14/2024	AdvisorShares Investments LLC	74,666	$0.31M	0.1%	-33.9%	0.248%
2/13/2024	Northern Trust Corp	96,267	$0.40M	0.0%	+104.4%	0.320%
1/31/2024	Federated Hermes Inc.	99,839	$0.41M	0.0%	-12.6%	0.332%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	270,396	$1.12M	0.0%	+4.4%	0.898%
1/22/2024	Parsons Capital Management Inc. RI	949,841	$3.93M	0.3%	-2.5%	3.156%
1/12/2024	Guild Investment Management Inc.	212,100	$0.88M	1.4%	+3.3%	0.705%
12/6/2023	Citigroup Inc.	99,523	$0.30M	0.0%	-16.6%	0.331%
11/17/2023	Jacobs Levy Equity Management Inc.	125,846	$0.38M	0.0%	N/A	0.418%
11/15/2023	GSA Capital Partners LLP	195,415	$0.59M	0.1%	-28.0%	0.649%
11/14/2023	Schonfeld Strategic Advisors LLC	109,310	$0.33M	0.0%	N/A	0.363%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	87,153	$0.26M	0.0%	-16.6%	0.290%
11/13/2023	Mariner LLC	23,253	$70K	0.0%	-24.7%	0.077%
11/13/2023	LPL Financial LLC	12,960	$39K	0.0%	N/A	0.043%
11/13/2023	Acadian Asset Management LLC	1,172,723	$3.51M	0.0%	-4.0%	3.896%
11/13/2023	Silverarc Capital Management LLC	100,000	$0.30M	0.1%	N/A	0.332%
11/9/2023	Citigroup Inc.	99,523	$0.30M	0.0%	-16.6%	0.331%
11/9/2023	UBS Group AG	125,688	$0.38M	0.0%	+27.0%	0.418%
11/6/2023	Parsons Capital Management Inc. RI	974,082	$2.92M	0.2%	+11.5%	3.236%
11/6/2023	Guild Investment Management Inc.	205,300	$0.62M	1.0%	+84.0%	0.682%
10/27/2023	TD Asset Management Inc	25,000	$75K	0.0%	+100.0%	0.083%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	259,009	$0.78M	0.0%	-23.6%	0.860%
10/24/2023	Bank of New York Mellon Corp	36,719	$0.11M	0.0%	-53.8%	0.122%
10/24/2023	Stratos Wealth Partners LTD.	16,000	$48K	0.0%	N/A	0.053%
9/21/2023	Barclays PLC	145,999	$0.36M	0.0%	+884.0%	0.485%
8/15/2023	XTX Topco Ltd	10,767	$26K	0.0%	-87.5%	0.036%
8/15/2023	Y Intercept Hong Kong Ltd	42,574	$0.11M	0.0%	N/A	0.141%
8/15/2023	Goldman Sachs Group Inc.	162,347	$0.40M	0.0%	-18.8%	0.539%
8/15/2023	RBF Capital LLC	194,074	$0.48M	0.0%	N/A	0.645%
8/14/2023	PDT Partners LLC	31,741	$78K	0.0%	-54.2%	0.105%
8/14/2023	Ergoteles LLC	27,100	$67K	0.0%	N/A	0.090%
8/14/2023	State Street Corp	129,429	$0.32M	0.0%	-76.5%	0.430%
8/11/2023	Renaissance Technologies LLC	132,772	$0.33M	0.0%	-57.6%	0.441%
8/11/2023	BlackRock Inc.	605,254	$1.49M	0.0%	-67.1%	2.011%
8/11/2023	The Manufacturers Life Insurance Company	20,343	$50K	0.0%	-18.7%	0.068%
8/11/2023	Geode Capital Management LLC	234,362	$0.58M	0.0%	-53.3%	0.779%
8/11/2023	Northern Trust Corp	47,450	$0.12M	0.0%	-77.4%	0.158%
8/10/2023	Bedel Financial Consulting Inc.	10,000	$25K	0.0%	N/A	0.033%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	338,945	$0.83M	0.0%	+17.3%	1.126%
8/10/2023	Charles Schwab Investment Management Inc.	12,505	$31K	0.0%	-83.1%	0.042%
8/10/2023	Citigroup Inc.	119,318	$0.29M	0.0%	N/A	0.396%
8/9/2023	AdvisorShares Investments LLC	112,898	$0.28M	0.1%	+8.4%	0.375%
8/7/2023	Tortoise Investment Management LLC	19,176	$47K	0.0%	+52.7%	0.064%
8/4/2023	Parsons Capital Management Inc. RI	873,312	$2.15M	0.2%	+20.9%	2.901%
8/3/2023	Barclays PLC	145,999	$0.36M	0.0%	+884.0%	0.485%
8/3/2023	Bank of New York Mellon Corp	79,428	$0.20M	0.0%	-48.3%	0.264%
7/20/2023	Guild Investment Management Inc.	111,550	$0.27M	0.4%	+7.4%	0.371%
6/1/2023	Prelude Capital Management LLC	16,700	$38K	0.0%	N/A	0.055%
5/18/2023	JPMorgan Chase & Co.	20,981	$47K	0.0%	+35.3%	0.070%
5/16/2023	Spotlight Asset Group Inc.	20,000	$0.14M	0.1%	N/A	0.066%
5/16/2023	State Street Corp	551,096	$1.25M	0.0%	+11.2%	1.831%
5/16/2023	Geode Capital Management LLC	502,343	$1.14M	0.0%	+3.3%	1.669%
5/16/2023	AQR Capital Management LLC	36,991	$84K	0.0%	+21.9%	0.123%
5/15/2023	Palo Alto Investors LP	542,100	$1.23M	0.1%	N/A	1.801%
5/15/2023	Two Sigma Advisers LP	357,600	$0.81M	0.0%	+10.7%	1.188%
5/15/2023	Two Sigma Investments LP	404,275	$0.91M	0.0%	-23.3%	1.343%
5/15/2023	Deutsche Bank AG	254,742	$0.58M	0.0%	+6.5%	0.846%
5/15/2023	Price T Rowe Associates Inc. MD	178,440	$0.40M	0.0%	-4.8%	0.593%
5/15/2023	RTW Investments LP	2,131,835	$4.82M	0.1%	+3.1%	7.083%
5/15/2023	XTX Topco Ltd	86,267	$0.20M	0.0%	-33.3%	0.287%
5/12/2023	Renaissance Technologies LLC	313,175	$0.71M	0.0%	+43.8%	1.040%
5/12/2023	BlackRock Inc.	1,838,417	$4.16M	0.0%	-1.3%	6.108%
5/12/2023	Bank of America Corp DE	37,334	$84K	0.0%	+125.4%	0.124%
5/12/2023	Sei Investments Co.	36,969	$84K	0.0%	-63.5%	0.123%
5/12/2023	Dimensional Fund Advisors LP	55,568	$0.13M	0.0%	-8.4%	0.185%
5/12/2023	Charles Schwab Investment Management Inc.	73,915	$0.17M	0.0%	+20.4%	0.246%
5/11/2023	Acadian Asset Management LLC	1,221,399	$2.76M	0.0%	+11.0%	4.058%
5/11/2023	FMR LLC	89,478	$0.20M	0.0%	+6.8%	0.297%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	109,959	$0.25M	0.0%	-7.3%	0.365%
5/9/2023	Tortoise Investment Management LLC	12,561	$28K	0.0%	+65.6%	0.042%
5/9/2023	AdvisorShares Investments LLC	104,140	$0.24M	0.1%	+28.0%	0.346%
5/9/2023	Bank of New York Mellon Corp	153,503	$0.35M	0.0%	-17.5%	0.510%
5/4/2023	Barclays PLC	14,838	$33K	0.0%	+102.5%	0.049%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	288,946	$0.65M	0.0%	+3.4%	0.960%
5/2/2023	Sargent Investment Group LLC	14,317	$34K	0.0%	N/A	0.048%
4/27/2023	Tiedemann Advisors LLC	30,215	$68K	0.0%	+49.5%	0.100%
4/18/2023	Guild Investment Management Inc.	103,900	$0.24M	0.4%	N/A	0.345%
4/17/2023	Parsons Capital Management Inc. RI	722,166	$1.63M	0.1%	+45.5%	2.399%
2/28/2023	Voya Investment Management LLC	10,752	$38K	0.0%	-47.1%	0.036%
2/16/2023	Alliancebernstein L.P.	30,400	$0.11M	0.0%	+69.8%	0.101%
2/16/2023	Point72 Middle East FZE	15,517	$54K	0.0%	N/A	0.052%
2/15/2023	Schonfeld Strategic Advisors LLC	75,300	$0.26M	0.0%	-50.0%	0.250%
2/15/2023	Squarepoint Ops LLC	35,281	$0.12M	0.0%	N/A	0.117%
2/15/2023	Tang Capital Management LLC	100,000	$0.35M	0.1%	-75.0%	0.332%
2/15/2023	Millennium Management LLC	1,061,774	$3.71M	0.0%	-5,364.1%	3.527%
2/15/2023	Morgan Stanley	488,739	$1.71M	0.0%	+67.0%	1.624%
2/15/2023	Mariner LLC	41,080	$0.14M	0.0%	N/A	0.136%
2/15/2023	AQR Capital Management LLC	30,343	$0.11M	0.0%	N/A	0.101%
2/15/2023	Boothbay Fund Management LLC	12,792	$45K	0.0%	N/A	0.042%
2/14/2023	Price T Rowe Associates Inc. MD	187,459	$0.65M	0.0%	-4.6%	0.623%
2/14/2023	Two Sigma Investments LP	527,162	$1.84M	0.0%	+916.0%	1.751%
2/14/2023	Arrowstreet Capital Limited Partnership	21,420	$75K	0.0%	N/A	0.071%
2/14/2023	Engineers Gate Manager LP	45,424	$0.16M	0.0%	N/A	0.151%

Data available starting January 2016

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Today's Range

Now: $4.68

$4.52

$4.72

50 Day Range

MA: $5.31

$4.44

$6.80

52 Week Range

Now: $4.68

$2.36

$7.22

Volume

85,164 shs

Average Volume

259,181 shs

Market Capitalization

$141.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Who are the company insiders with the largest holdings of Relmada Therapeutics?: Relmada Therapeutics' top insider shareholders include:
Sergio Traversa (CEO)
Maged Shenouda (CFO)
Chuck Ence (Insider)
Cedric O'gorman (Insider)
Learn More about top insider investors at Relmada Therapeutics.